[Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin].
BACKGROUND
The development of factor V inhibitor is very rare, especially in combination with antiphospholipid antibodies.


METHODS
The paper describes the course of two patients with factor V inhibitor, antiphospholipid antibodies and massive bleeding symptoms after treatment with ciprofloxacin. At that time, ciprofloxacin was the only new drug given. DIAGNOSIS AND CLINICAL COURSE: First changes of the coagulation system were detected 4 days after start of treatment. In one case, occurrence was transient, and normalization was observed after terminating ciprofloxacin treatment. The other case ended with massive muscular and visceral bleedings and cardiovascular failure. Factor V inhibitor and antiphospholipid antibodies could be demonstrated even after termination of ciprofloxacin therapy.


CONCLUSIONS
The association of treatment with ciprofloxacin and development of factor V inhibitor and antiphospholipid antibodies is probably diagnosed to rarely. These two cases emphasize the necessity of meticulous clarification of a prolonged activated partial thromboplastin time (aPTT) and a drop in prothrombin time (PT) during and after ciprofloxacin treatment.
Miesbach
Wolfgang
W
Medizinische Klinik I, Hämostaseologie, Johann Wolfgang Goethe-Universität, Frankfurt/Main. miesbach@em.uni-frankfurt.de
Voigt
Jochen
J
Peetz
Dirk
D
Scharrer
Inge
I
D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017152:Antibodies, Antiphospholipid; D001780:Blood Coagulation Tests; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects*; D005165:Factor V / Q000037:antagonists & inhibitors*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D010314:Partial Thromboplastin Time; D013997:Time Factors
D000890:Anti-Infective Agents; D017152:Antibodies, Antiphospholipid; D002939:Ciprofloxacin; D005165:Factor V